UroGen Pharma Analyst Ratings
UroGen Pharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/15/2023 | 182.19% | Oppenheimer | $33 → $32 | Maintains | Outperform |
| 10/04/2023 | 376.19% | HC Wainwright & Co. | → $54 | Reiterates | Buy → Buy |
| 08/14/2023 | 376.19% | HC Wainwright & Co. | → $54 | Reiterates | Buy → Buy |
| 08/01/2023 | 376.19% | HC Wainwright & Co. | $23 → $54 | Maintains | Buy |
| 07/31/2023 | 58.73% | Goldman Sachs | $11 → $18 | Maintains | Neutral |
| 06/21/2023 | 102.82% | HC Wainwright & Co. | → $23 | Reiterates | Buy → Buy |
| 05/15/2023 | 94% | Oppenheimer | → $22 | Reiterates | Outperform → Outperform |
| 05/15/2023 | 102.82% | HC Wainwright & Co. | → $23 | Reiterates | Buy → Buy |
| 05/02/2023 | 102.82% | HC Wainwright & Co. | → $23 | Reiterates | → Buy |
| 04/10/2023 | 102.82% | HC Wainwright & Co. | → $23 | Reiterates | → Buy |
| 02/16/2023 | 102.82% | HC Wainwright & Co. | → $23 | Reiterates | → Buy |
| 02/08/2023 | -11.82% | Jefferies | $35 → $10 | Downgrades | Buy → Hold |
| 12/12/2022 | 102.82% | HC Wainwright & Co. | $26 → $23 | Maintains | Buy |
| 04/27/2022 | 76.37% | Berenberg | → $20 | Initiates Coverage On | → Buy |
| 03/22/2022 | -3% | Goldman Sachs | $10 → $11 | Maintains | Neutral |
| 01/18/2022 | 199.82% | HC Wainwright & Co. | $50 → $34 | Maintains | Buy |
| 04/27/2021 | 340.92% | HC Wainwright & Co. | $57 → $50 | Maintains | Buy |
| 04/17/2020 | 314.46% | Oppenheimer | $45 → $47 | Maintains | Outperform |
| 04/16/2020 | 402.65% | HC Wainwright & Co. | $53 → $57 | Reiterates | → Buy |
| 04/13/2020 | 367.37% | HC Wainwright & Co. | $75 → $53 | Maintains | Buy |
| 04/06/2020 | 296.83% | Oppenheimer | $47 → $45 | Maintains | Outperform |
| 01/13/2020 | 358.55% | Oppenheimer | $62 → $52 | Maintains | Outperform |
| 11/13/2019 | 243.92% | JP Morgan | $40 → $39 | Maintains | Neutral |
| 05/30/2019 | 261.55% | JP Morgan | → $41 | Initiates Coverage On | → Neutral |
| 05/29/2019 | 340.92% | Goldman Sachs | → $50 | Initiates Coverage On | → Neutral |
| 01/29/2019 | 623.1% | HC Wainwright & Co. | → $82 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/15/2023 | 182.19% | 奧本海默 | 33 美元 → 32 美元 | 維護 | 跑贏大盤 |
| 2023 年 4 月 10 日 | 376.19% | HC Wainwright & Co. | → 54 美元 | 重申 | 購買 → 購買 |
| 08/14/2023 | 376.19% | HC Wainwright & Co. | → 54 美元 | 重申 | 購買 → 購買 |
| 08/01/2023 | 376.19% | HC Wainwright & Co. | 23 美元 → 54 美元 | 維護 | 買 |
| 07/31/2023 | 58.73% | 高盛 | 11 美元 → 18 美元 | 維護 | 中立 |
| 06/21/2023 | 102.82% | HC Wainwright & Co. | → 23 美元 | 重申 | 購買 → 購買 |
| 05/15/2023 | 94% | 奧本海默 | → 22 美元 | 重申 | 跑贏大盤 → 跑贏大盤 |
| 05/15/2023 | 102.82% | HC Wainwright & Co. | → 23 美元 | 重申 | 購買 → 購買 |
| 05/02/2023 | 102.82% | HC Wainwright & Co. | → 23 美元 | 重申 | → 購買 |
| 2023 年 10 月 4 日 | 102.82% | HC Wainwright & Co. | → 23 美元 | 重申 | → 購買 |
| 02/16/2023 | 102.82% | HC Wainwright & Co. | → 23 美元 | 重申 | → 購買 |
| 02/08/2023 | -11.82% | 傑富瑞集團 | 35 美元 → 10 美元 | 降級 | 買入 → 持有 |
| 2022 年 12 月 12 日 | 102.82% | HC Wainwright & Co. | 26 美元 → 23 美元 | 維護 | 買 |
| 04/27/2022 | 76.37% | 貝倫貝格 | → 20 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 03/22/2022 | -3% | 高盛 | 10 美元 → 11 美元 | 維護 | 中立 |
| 01/18/2022 | 199.82% | HC Wainwright & Co. | 50 美元 → 34 美元 | 維護 | 買 |
| 04/27/2021 | 340.92% | HC Wainwright & Co. | 57 美元 → 50 美元 | 維護 | 買 |
| 2020 年 4 月 17 日 | 314.46% | 奧本海默 | 45 美元 → 47 美元 | 維護 | 跑贏大盤 |
| 2020 年 4 月 16 日 | 402.65% | HC Wainwright & Co. | 53 美元 → 57 美元 | 重申 | → 購買 |
| 2020 年 4 月 13 日 | 367.37% | HC Wainwright & Co. | 75 美元 → 53 美元 | 維護 | 買 |
| 2020 年 6 月 4 日 | 296.83% | 奧本海默 | 47 美元 → 45 美元 | 維護 | 跑贏大盤 |
| 2020 年 1 月 13 日 | 358.55% | 奧本海默 | 62 美元 → 52 美元 | 維護 | 跑贏大盤 |
| 11/13/2019 | 243.92% | 摩根大通 | 40 美元 → 39 美元 | 維護 | 中立 |
| 2019 年 5 月 30 日 | 261.55% | 摩根大通 | → 41 美元 | 啓動覆蓋範圍開啓 | → 中立 |
| 05/29/2019 | 340.92% | 高盛 | → 50 美元 | 啓動覆蓋範圍開啓 | → 中立 |
| 2019 年 1 月 29 日 | 623.1% | HC Wainwright & Co. | → 82 美元 | 啓動覆蓋範圍開啓 | → 購買 |
What is the target price for UroGen Pharma (URGN)?
UroGen Pharma（URGN）的目標價格是多少？
The latest price target for UroGen Pharma (NASDAQ: URGN) was reported by Oppenheimer on November 15, 2023. The analyst firm set a price target for $32.00 expecting URGN to rise to within 12 months (a possible 182.19% upside). 13 analyst firms have reported ratings in the last year.
奧本海默於2023年11月15日公佈了UroGen Pharma（納斯達克股票代碼：URGN）的最新目標股價。該分析公司將目標股價定爲32.00美元，預計URGN將在12個月內升至12個月內（可能上漲182.19％）。去年有13家分析公司公佈了評級。
What is the most recent analyst rating for UroGen Pharma (URGN)?
分析師對UroGen Pharma（URGN）的最新評級是多少？
The latest analyst rating for UroGen Pharma (NASDAQ: URGN) was provided by Oppenheimer, and UroGen Pharma maintained their outperform rating.
UroGen Pharma（納斯達克股票代碼：URGN）的最新分析師評級由奧本海默提供，UroGen Pharma維持跑贏大盤的評級。
When is the next analyst rating going to be posted or updated for UroGen Pharma (URGN)?
UroGen Pharma（URGN）的下一次分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of UroGen Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for UroGen Pharma was filed on November 15, 2023 so you should expect the next rating to be made available sometime around November 15, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與UroGen Pharma的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。UroGen Pharma的最新評級是在2023年11月15日公佈的，因此您應該預計下一個評級將在2024年11月15日左右公佈。
Is the Analyst Rating UroGen Pharma (URGN) correct?
分析師對UroGen Pharma（URGN）的評級是否正確？
While ratings are subjective and will change, the latest UroGen Pharma (URGN) rating was a maintained with a price target of $33.00 to $32.00. The current price UroGen Pharma (URGN) is trading at is $11.34, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的UroGen Pharma（URGN）評級維持不變，目標股價爲33.00美元至32.00美元。UroGen Pharma（URGN）目前的交易價格爲11.34美元，超出了分析師的預期區間。